MedTrace Logo

A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects

NCT00121017 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2006-07-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether a simplified lopinavir/ritonavir-based therapy will continue to keep the viral load at very low levels after initial treatment with a combination of Kaletra (lopinavir/ritonavir) plus tenofovir and emtricitabine.

Conditions

  • HIV Infection
  • Hepatitis C

Interventions

DRUG

Kaletra (lopinavir/ritonavir)

DRUG

Sustiva (efavirenz)

DRUG

Truvada (emtricitabine/tenofovir disoproxil fumarate)

Sponsors & Collaborators

Principal Investigators

  • Global Medical Information · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00121017 on ClinicalTrials.gov